在印度,诺沃北欧公司将Ozempic和Wegovy的价格降低48%. Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% in India.

诺沃北方公司在印度降低了糖尿病和肥胖药物Ozempic和Wegovy的价格,高达48%,自4月1日起生效.此前,西马古胺专利已经过期. Novo Nordisk has lowered prices for its diabetes and obesity drugs Ozempic and Wegovy in India by up to 48%, effective April 1, following the expiration of the patents on semaglutide. 为了改善糖尿病和肥胖症严重的患者在该国获得药物治疗, This move responds to the entry of cheaper generic versions and aims to improve access for patients in a country with a large burden of diabetes and obesity.